citalopram hydrobromide solution
aurobindo pharma limited - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg in 5 ml - citalopram oral solution, usp is indicated for the treatment of depression. the efficacy of citalopram oral solution, usp in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram oral solution, usp in hospitalized depressed patients has no
citalopram hydrobromide solution
lannett company, inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg in 5 ml - citalopram oral solution, usp is indicated for the treatment of depression. the efficacy of citalopram oral solution, usp in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram oral solution, usp in hospitalized depressed patients has not been a
citalopram solution
hikma pharmaceuticals usa inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg in 5 ml - citalopram oral solution is indicated for the treatment of depression. the efficacy of citalopram oral solution in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram oral solution in hospitalized depressed patients has not been adequately studie
citalopram hydrobromide solution
atlantic biologicals corp. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram oral solution, usp is indicated for the treatment of depression. the efficacy of citalopram oral solution, usp in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram oral solution, usp in hospitalized depressed patients has not bee
citalopram solution
chartwell rx, llc - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram oral solution is indicated for the treatment of depression. the efficacy of citalopram oral solution in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder ( see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram oral solution in hospitalized depressed
lexapro
pharmacy retailing (nz) ltd t/a healthcare logistics - escitalopram oxalate 12.77mg equivalent to escitalopram 10 mg; - film coated tablet - 10 mg - active: escitalopram oxalate 12.77mg equivalent to escitalopram 10 mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose macrogol 400 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - in adults: treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.
lexapro
pharmacy retailing (nz) ltd t/a healthcare logistics - escitalopram oxalate 19.16mg equivalent to escitalopram 15 mg; ; - film coated tablet - 15 mg - active: escitalopram oxalate 19.16mg equivalent to escitalopram 15 mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose macrogol 400 magnesium stearate microcrystalline cellulose purified talc titanium dioxide
lexapro
pharmacy retailing (nz) ltd t/a healthcare logistics - escitalopram oxalate 25.54mg equivalent to escitalopram 20 mg; - film coated tablet - 20 mg - active: escitalopram oxalate 25.54mg equivalent to escitalopram 20 mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose macrogol 400 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - in adults: treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.
lexapro
pharmacy retailing (nz) ltd t/a healthcare logistics - escitalopram oxalate 6.39mg equivalent to escitalopram 5 mg; ; - film coated tablet - 5 mg - active: escitalopram oxalate 6.39mg equivalent to escitalopram 5 mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose macrogol 400 magnesium stearate microcrystalline cellulose purified talc titanium dioxide
lexapro 15 mg film-coated tablets
primecrown 2010 limited - escitalopram - film-coated tablet - 15 milligram(s) - selective serotonin reuptake inhibitors; escitalopram